PARACETAMOL B. BRAUN 10MG/ML Infuzní roztok Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol b. braun 10mg/ml infuzní roztok

b. braun melsungen ag, melsungen array - 1064 paracetamol - infuzní roztok - 10mg/ml - paracetamol

PARACETAMOL/IBUPROFEN ZENTIVA 500MG/200MG Potahovaná tableta Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol/ibuprofen zentiva 500mg/200mg potahovaná tableta

zentiva, k.s., praha array - 1064 paracetamol; 1593 ibuprofen - potahovaná tableta - 500mg/200mg - paracetamol, kombinace kromĚ psycholeptik

PARACETAMOL/KOFEIN DR. MÜLLER PHARMA 500MG/65MG Tableta Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol/kofein dr. müller pharma 500mg/65mg tableta

dr. müller pharma s.r.o., hradec králové array - 1064 paracetamol; 223 kofein - tableta - 500mg/65mg - paracetamol, kombinace kromĚ psycholeptik

PARACETAMOL NORIDEM 10MG/ML Infuzní roztok Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol noridem 10mg/ml infuzní roztok

noridem enterprises limited, nikosia array - 1064 paracetamol - infuzní roztok - 10mg/ml - paracetamol

PARACETAMOL PHARMACLAN 1000MG Potahovaná tableta Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol pharmaclan 1000mg potahovaná tableta

pharmaclan s.r.o., praha array - 1064 paracetamol - potahovaná tableta - 1000mg - paracetamol

PARACETAMOL STADA 600MG Prášek pro perorální roztok v sáčku Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol stada 600mg prášek pro perorální roztok v sáčku

stada arzneimittel ag, bad vilbel array - 1064 paracetamol - prášek pro perorální roztok v sáčku - 600mg - paracetamol

Imatinib Accord Unjoni Ewropea - Ċek - EMA (European Medicines Agency)

imatinib accord

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. kromě nově diagnostikované chronické fáze cml nejsou k dispozici kontrolované studie, které by prokázaly klinický přínos nebo prodloužené přežití u těchto uvedených onemocnění. .

PARACETAMOL/PHENYLEPHRINE HYDROCHLORIDE/ASCORBIC ACID OMEGA PHARMA 300MG/5MG/20MG Prášek pro perorální roztok v sáčku Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol/phenylephrine hydrochloride/ascorbic acid omega pharma 300mg/5mg/20mg prášek pro perorální roztok v sáčku

omega pharma a.s., brno array - 1064 paracetamol; 1122 fenylefrin-hydrochlorid; 102 kyselina askorbovÁ - prášek pro perorální roztok v sáčku - 300mg/5mg/20mg - paracetamol, kombinace kromĚ psycholeptik

TRAMADOL/PARACETAMOL MEDREG 37,5MG/325MG Potahovaná tableta Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

tramadol/paracetamol medreg 37,5mg/325mg potahovaná tableta

medreg s.r.o., praha array - 2719 tramadol-hydrochlorid; 1064 paracetamol - potahovaná tableta - 37,5mg/325mg - tramadol a paracetamol

PARACETAMOL AGMED 500MG Tableta Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

paracetamol agmed 500mg tableta

agmed s.r.o., ostrava array - 1064 paracetamol - tableta - 500mg - paracetamol